Pneumococcal Vaccination (Pneumonia Vaccine)

Title: Pneumococcal Vaccination (Pneumonia Vaccine)Category: Procedures and TestsCreated: 4/12/1999 12:00:00 AMLast Editorial Review: 6/11/2018 12:00:00 AM
Source: MedicineNet Lungs General - Category: Respiratory Medicine Source Type: news

Related Links:

CONCLUSION: The results suggest that vaccinating home care patients could potentially be cost-saving from the health care and service producer's perspectives. The uncertainty from the decision-making perspective was due to the large variation in individual costs. PMID: 30114939 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Publication date: Available online 14 August 2018Source: Microbial PathogenesisAuthor(s): Min Yong Jwa, Eun Byeol Ko, Hyun Young Kim, Sun Kyung Kim, Soyoung Jeong, Ho Seong Seo, Cheol-Heui Yun, Seung Hyun HanAbstractStreptococcus pneumoniae is a major respiratory pathogen that can cause pneumonia, meningitis, and otitis media. Although capsular polysaccharide-based vaccines are commercially available, there is a need for broad-spectrum, serotype-independent, and cost-effective vaccines. Recently, an intranasal vaccine formulated with gamma-irradiated nonencapsulated S. pneumoniae whole cells has been developed and its immu...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
This study sought to evaluate and contribute to the limited data on U.S. hospital practice patterns with respect to respiratory vaccination in patients hospitalized with heart failure (HF).BackgroundRespiratory infection is a major driver of morbidity in patients with HF, and many influenza and pneumococcal infections may be prevented by vaccination.MethodsWe evaluated patients hospitalized at centers participating in the Get With The Guidelines–HF (GWTG-HF) registry from October 2012 to March 2017. The proportion of patients receiving vaccination was described for influenza and pneumococcal vaccination, respectively...
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
Calvin Green, Christine Ann Moore, Akhilesh Mahajan, Kailash BajajJournal of Global Infectious Diseases 2018 10(3):159-162 Streptococcus pneumoniae is a bacterium responsible for a spectrum of diseases including lobar pneumonia, meningitis, otitis media, and sinusitis. Invasive pneumococcal disease is responsible for significant morbidity and mortality across the world. Concerted efforts led to the development of two vaccinations, Pneumova × 23 and Prevnar 13, for the prevention of pneumococcal disease. The Advisory Committee on Immunization Practices of the US Centers for Disease Control and Prevention provides vacc...
Source: Journal of Global Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
Conditions:   Multiple Myeloma;   Pneumococcal Infection;   Febrile Neutropenia;   Pneumococcal Pneumonia Interventions:   Biological: Vaccination with pneumococcal conjugate vaccine (PCV13);   Drug: Standard Antibacterial Prophylaxis Sponsors:   Minsk State Clinical Hospital No 9;   Belarusian state medical university Enrolling by invitation
Source: - Category: Research Source Type: clinical trials
Streptococccus pneumoniae is a major cause of disease and death globally with the highest incidence occurring in children less than 5 and older adults and in low income countries. Development of pneumococcal conjugate vaccination (PCV), against the most common disease-causing serotypes, has been an important advancement in prevention of disease with documented effectiveness for invasive pneumococcal disease, pneumonia and otitis media in countries incorporating the vaccine in their national immunization programs.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Type: Invited Presentation Source Type: research
Background: Pneumonia has been one of leading causes of childhood mortality in Colombia. Since 2006, the Colombian Ministry of Health recommends pneumococcal conjugate vaccine (PCV) to high-risk groups. The universal mass vaccination program was fully implemented in 2011 (2-4-12-month schedule). In 2012, Pneumococcal polysaccharide protein D-conjugate vaccine replaced the use of 7-valent PCV. The aim of the current study is to describe trends in pneumonia-related mortality in Colombian children, before and after the introduction of the PCV program.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: UMP. 325 Source Type: research
Background: CAPiTA study found significant efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) for first episode of vaccine-type community-acquired pneumonia (CAP), nonbacteremic/noninvasive vaccine-type CAP and vaccine-type CAP invasive pneumococcal disease.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: UMP. 721 Source Type: research
Background: Pneumococcal pneumonia is an important cause of morbi-mortality in argentinian adult population. In immunocompromised hosts and patients with known risk factors, the risk of infection by this pathogen is elevated. According to the Third National Enquiry of Risk Factors (Argentina 2013), the prevalence of application of pneumococcal vaccine is 16.2% (CI 95% 15.2-17.3), which demonstrates the limited adhesion to the practice guidelines by medical doctors. The immunization rate of private health care providers is unknown.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: UMP. 718 Source Type: research
Abstract Pneumonia and diarrhea are the leading causes of child morbidity and mortality globally and are vaccine preventable. The WHO-coordinated Global Rotavirus and Invasive Bacterial Vaccine-Preventable Disease Surveillance Networks support surveillance systems across WHO regions to provide burden of disease data for countries to make evidence-based decisions about introducing vaccines and to demonstrate the impact of vaccines on disease burden. These surveillance networks help fill the gaps in data in low and middle-income countries where disease burden and risk are high but support to sustain surveillance act...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
More News: Meningitis Vaccine | Pneomococcal Vaccine | Pneumonia | Respiratory Medicine | Vaccines